The CRISPR/Cas9 system allows for unprecedented ease and control when editing the genome. Its potential impact on drug discovery is vast, including enabling gene and cell replacement therapies, identifying novel drug targets through functional genomic screens, and simplifying the production of disease models using permanent knockouts for validating therapy targets and testing drug efficacy. But in practical terms, how is CRISPR/Cas9 currently being applied, and where might the future challenges and pitfalls be? Furthermore, how do assays based on the new CRISPR/Cas9 technology compare with current screening methodologies, particularly those using small interfering RNA (siRNA)?
During this webinar, our expert panel will address:
- Areas of the drug discovery process where gene editing will have the most immediate and long term impact
- The current and future role of CRISPR/Cas9 in target discovery, hit identification, and lead optimization (compared with siRNA screening)
- The challenges that CRISPR/Cas9 brings to screening and assay development, particularly with respect to cell analysis
- The importance of carrying out binding studies following gene editing.
The presentations will be followed by a live Q&A session with the online audience.
The webinar will last approximately 60 minutes and will be followed by a live webchat (see below).
To learn more about products or technologies related to this webinar, go to: http://dharmaconinfo.gelifesciences.com/drug-discovery-suite